Key result
TriArtic TEER procedure reduces tricuspid annular area by ~11%, enabling successful EVOQUE valve implantation.
Why the study?
A prohibitively dilated tricuspid annulus may exceed EVOQUE device-sizing parameters and preclude transcatheter tricuspid valve replacement, with no described transcatheter strategy to mechanically pre-condition such an annulus.
Case Report (n=1)
A strategically placed commissural TEER device can successfully reduce a prohibitively dilated tricuspid annulus, thereby enabling subsequent transcatheter tricuspid valve replacement with the EVOQUE system.
Answers are grounded in this paper and cite their sources.
Commissural TEER may enable EVOQUE implantation in oversized annuli; hypothesis-generating case report requiring prospective validation.
Background Transcatheter tricuspid valve replacement (TTVR) with the EVOQUE system has expanded therapeutic options for severe tricuspid regurgitation (TR), but a prohibitively dilated tricuspid annulus may exceed the device-sizing matrix and preclude implantation. No transcatheter strategy has been described to mechanically pre-condition such an annulus. Case summary A 71-year-old woman with HFrEF (LVEF 38%, suspected premature-ventricular-complex–induced cardiomyopathy), permanent atrial fibrillation and class III obesity presented with torrential atrial functional TR refractory to fully optimised guideline-directed medical therapy. Screening cardiac computed tomography (CT) classified the native annulus as “outside parameters” for the 56 mm EVOQUE (Edwards Lifesciences); the Heart Team also deemed standalone tricuspid edge-to-edge repair (T-TEER) inadequate owing to the massively dilated annulus. We performed the TriArtic procedure—a single TriClip XTW (Abbott) deployed in the septo-anterior position as a transcatheter annuloplasty step. Repeat CT after 27 days demonstrated an ∼11% reduction in tricuspid annular area and conversion of projected-derived-diameter oversizing from –2.9% to +3.3% (within parameters). Transfemoral EVOQUE 56 mm was implanted 48 days after the TriClip; postprocedural imaging confirmed no residual regurgitation and a mean transtricuspid gradient of 1 mm Hg, with rapid recovery of cardiorenal function. Discussion Transcatheter tricuspid annuloplasty by a strategically placed commissural TEER device may convert a prohibitively dilated annulus into one within EVOQUE-implantable parameters. In carefully selected patients ineligible for either standalone strategy, sequential transcatheter annuloplasty followed by valve replacement—the TriArtic procedure—may offer a feasible pathway, conceptually analogous to the mitral ARCTIC technique. This single case demonstrates feasibility only and does not establish general applicability.
No takes yet. Share an insight, caveat, or question.
Phinicarides et al. (2026) conducted a case report in Severe tricuspid regurgitation with prohibitively dilated tricuspid annulus (n=1). TriArtic procedure (single TriClip XTW followed by EVOQUE 56 mm tricuspid valve replacement) was evaluated on Reduction in tricuspid annular area and conversion of projected-derived-diameter oversizing. The TriArtic procedure, utilizing a strategically placed commissural TEER device, reduced tricuspid annular area by ~11%, enabling successful EVOQUE valve implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: